AI English summary of an SEC filing — figures as filed
IDEXX Laboratories IDXXIDEXX Laboratories entered into Amendment No. 2 to the Fourth Amended and Restated Credit Agreement on November 12, 2025. The company said the term loan facility matures 3 years from the closing date of the Amendment and the revolving credit facility matures 5 years from the closing date.
Key points
AI summaryIDEXX Laboratories entered into Amendment No. 2 to the Fourth Amended and Restated Credit Agreement on November 12, 2025. The company said the term loan facility matures 3 years from the closing date of the Amendment and the revolving credit facility matures 5 years from the closing date.
Under the Credit Agreement, the company said there remains an unsecured revolving credit facility in the principal amount of $1.0 billion, an unsecured term loan in the principal amount of $250 million, and flexibility to incur incremental revolving credit commitments and/or term loans in the aggregate principal amount of up to $250 million.
For borrowings in United States Dollars, IDEXX Laboratories said the adjusted Term SOFR Rate carries a margin ranging from 0.875% to 1.375% based on the company's consolidated leverage ratio, plus 0.10%. The company added that if the base rate option is selected, the margin ranges from 0.0% to 0.375%.
IDEXX Laboratories said IDEXX Holdings II GmbH assumes all the rights and obligations of a Borrower under the Credit Agreement. The company added that IDEXX Distribution, Inc., IDEXX Operations, Inc., and OPTI Medical Systems, Inc. unconditionally guarantee the obligations of the borrowers. The financial covenant is a consolidated leverage ratio test.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Amendment No. 2 Entered Into and Maturity Extended
IDEXX Laboratories entered into Amendment No. 2 to the Fourth Amended and Restated Credit Agreement on November 12, 2025. The company said the term loan facility matures 3 years from the closing date of the Amendment and the revolving credit facility matures 5 years from the closing date.
Source · Based on the filing body and exhibits
Credit Agreement Structure: $1.0 billion Revolving Facility and $250 million Term Loan
Under the Credit Agreement, the company said there remains an unsecured revolving credit facility in the principal amount of $1.0 billion, an unsecured term loan in the principal amount of $250 million, and flexibility to incur incremental revolving credit commitments and/or term loans in the aggregate principal amount of up to $250 million.
Source · Based on the filing body and exhibits
Borrowing Rates and Margins Tied to Consolidated Leverage Ratio
For borrowings in United States Dollars, IDEXX Laboratories said the adjusted Term SOFR Rate carries a margin ranging from 0.875% to 1.375% based on the company's consolidated leverage ratio, plus 0.10%. The company added that if the base rate option is selected, the margin ranges from 0.0% to 0.375%.
Source · Based on the filing body and exhibits
Guarantees, Financial Covenants and IDEXX Holdings II GmbH Borrower Status
IDEXX Laboratories said IDEXX Holdings II GmbH assumes all the rights and obligations of a Borrower under the Credit Agreement. The company added that IDEXX Distribution, Inc., IDEXX Operations, Inc., and OPTI Medical Systems, Inc. unconditionally guarantee the obligations of the borrowers. The financial covenant is a consolidated leverage ratio test.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…